123344-02-5

Basic information

• Product Name: 2,4-DIFLUORO-5-NITROANILINE
• Synonyms: 2,4-DIFLUORO-5-NITROANILINE
• CAS NO: 123344-02-5
• Molecular Formula: C₆H₄F₂N₂O₂
• Molecular Weight: 174.1
• Product Categories: Fluorine series
• Mol File: 123344-02-5.mol
• Article Data: 11

Chemical Properties

• Melting Point: 94-96°C
• Boiling Point: 309.4°C at 760 mmHg
• Flash Point: 140.9°C
• Appearance: /
• Density: 1.554g/cm³
• Vapor Pressure: 0.00064mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 1.02±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIFLUORO-5-NITROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIFLUORO-5-NITROANILINE(123344-02-5)
• EPA Substance Registry System: 2,4-DIFLUORO-5-NITROANILINE(123344-02-5)

Safety Data

• Hazardous Substances Data: 123344-02-5(Hazardous Substances Data)

Usage

General Description

2,4-Difluoro-5-nitroaniline is a chemical compound with the molecular formula C6H4F2N2O2. It is a nitroaniline derivative, meaning it contains a nitro group (NO2) and an aniline group (C6H5NH2). 2,4-DIFLUORO-5-NITROANILINE is commonly used in organic synthesis and pharmaceutical research due to its versatile chemical properties. 2,4-Difluoro-5-nitroaniline is often used as a building block for the production of various organic chemicals, including dyes and pharmaceuticals. Its unique structure and reactivity make it a valuable tool in the development of new chemical compounds for a variety of applications. However, it is important to handle this chemical with care, as it can be toxic and harmful if not properly managed.

InChI:InChI=1/C6H4F2N2O2/c7-3-1-4(8)6(10(11)12)2-5(3)9/h1-2H,9H2

Upstream product

• 446-35-5 2,4-Difluoronitrobenzene 
• 367-25-9 2,4-difluorophenylamine 
• 327-92-4 1,5-difluoro-2,4-dinitrobenzene 

Downstream Products

• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 
• 1421373-65-0 [N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)propen-2-amide] 
• 1421372-66-8 N?2?[[2?(dimethylamino)ethyl]methylamino]?4?methoxy?5?[[4?(1?methyl?1H?indole-3-yl)-2-pyrimidinyl]amino]aniline 
• 1421372-67-9 N¹-(2-(dimethylamino)ethyl)-5-methoxy-N¹-methyl-N⁴-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-2-nitrobenzene-1,4-diamine 
• 1421372-94-2 N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)-pyrimidine-2-amine 

Relevant articles and documents

Pyrimidine heterocyclic compounds, preparation method and application thereof

The present invention relates to compounds of a formula (I) shown in the description, and pharmaceutically acceptable salts, prodrugs and solvates thereof, and the compounds are useful for treating cancer and inflammation in mammals. The invention also discloses a preparation method for the compounds of the formula (I) and a pharmaceutical composition containing the compound.

Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine

We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I1/2 binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.